[The assessment of right ventricular function in patients with pulmonary arterial hypertension with cardiac magnetic resonance imaging: a Meta-analysis].
To explore the clinical value of cardiac magnetic resonance imaging (CMRI) in assessment of right ventricular function in patients with pulmonary arterial hypertension (PAH). The PubMed/MEDLINE, Wanfang data, CNKI (from January 2001 to April 2015) were searched. The search terms were pulmonary arterial hypertension, right ventricular function, and cardiac magnetic resonance imaging. An inclusion criterion was the patients suffering from PAH, and the healthy volunteers were served as controls. The study was designed as randomized controlled trial. All the subjects investigated had received CMRI. The end of the trial included right ventricular end diastolic volume (RVEDV), right ventricular end systolic volume (RVESV) and right ventricular ejection fraction (RVEF). Meta analysis was conducted by RevMan 5.0 software provided by Cochrane Collaboration, and the publication bias was analyzed by the funnel plot analysis. Five papers involving 381 patients met the criteria. It was showed by Meta-analysis that compared with healthy control group, RVEDV was increase in PAH group [weighted mean difference (WMD) = 33.96, 95% confidence interval (95% CI) = 20.80-47.12, P < 0.00001], RVESV was increased (WMD = 41.91, 95% CI = 29.63-54.19, P < 0.00001), and RVEF was decrease (WMD = -20.09, 95% CI = -22.65 to -17.52, P < 0.00001). CMRI can be used to evaluate the right ventricular function of patients with PAH, and it has important significance in the evaluation of right ventricular function in patients with PAH.